Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Study termination based on sponsor decision due to lack of tolerability observed with capmatinib and spartalizumab combination treatment when compared to data from capmatinib single agent studies

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: Spartalizumab
DRUG: Capmatinib
DRUG: spartalizumab placebo

Sponsor

Novartis Pharmaceuticals